Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
2 hedge funds and large institutions have $2.52K invested in Mirati Therapeutics, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 212 closing their positions.
99% less funds holding
Funds holding: 217 → 2 (-215)
100% less funds holding in top 10
Funds holding in top 10: 18 → 0 (-18)
100% less capital invested
Capital invested by funds: $4.66B → $2.52K (-$4.66B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 212
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$435M |
| 2 |
RI
RTW Investments
New York
|
-$398M |
| 3 |
Morgan Stanley
New York
|
-$362M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$312M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$287M |
MRTX Hedge Fund Activity: Q1 2024 in Review
2 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2024, worth a combined $2.52K — down 100% from $4.66B a quarter earlier.
Sellers outnumbered buyers: 212 funds closed out of MRTX and 0 opened new positions — a net loss of 212 holders — while 1 trimmed existing stakes and 0 added.
The largest seller was EcoR1 Capital, exiting entirely with an estimated $435M sold.
- 2 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2024, down from 217 in Q4 2023.
- Funds reported $2.52K of Mirati Therapeutics, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2024 and 212 closed out, a net change of -212 holders.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2024 was EcoR1 Capital, an estimated $435M sold.
Based on aggregated 13F filings for Q1 2024.